1. |
Sweeney C, Chen Y, Carducci M, et al. Chemohormonal therapy versus hormonal therapy for hormone naïve high volume newly metastatic prostate cancer (PrCa): ECOG led phase Ⅲ randomized. Ann Oncol, 2014, 25(4): iv255-iv279.
|
2. |
Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol, 2013, 14(2): 149-158.
|
3. |
Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351(15): 1502-1512.
|
4. |
Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol, 2008, 26(2): 242-245.
|
5. |
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 2004, 351(15): 1513-1520.
|
6. |
Yanagimoto H, Ishii H, Nakai Y, et al. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. J Hepatobiliary Pancreat Sci, 2014, 21(10): 761-766.
|
7. |
中国抗癌协会泌尿肿瘤专业委员会. 中国去势抵抗性前列腺癌诊治专家共识. 中华外科杂志, 2016, 54(7): 481-484.
|
8. |
Scher HI, Eisenberger M, D’amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 2004, 22(3): 537-556.
|
9. |
Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol, 2012, 61(6): 1079-1092.
|
10. |
Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor-activity of gemcitabine (2’,2’-difluoro-2’-deoxycytidine). Cancer Res, 1990, 50(14): 4417-4422.
|
11. |
Cronauer MV, Klocker H, Talasz H, et al. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate, 1996, 28(3): 172-181.
|
12. |
Morant R, Bernhard J, Maibach R, et al. For the swiss group for clinical cancer R (2000) response and palliation in a phase Ⅱ trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Ann Oncol, 2000, 11(2): 183-188.
|
13. |
Di Lorenzo G, Autorino R, Giuliano M, et al. phase Ⅱ trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology, 2007, 69(2): 347-351.
|
14. |
Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs, 1996, 7(5): 548-557.
|
15. |
Li Y, Mizutani Y, Shiraishi T, et al. The significance of the of dihydropyrimidine dehydrogenase in prostate cancer. BJU Int., 2007, 99(3): 663-668.
|
16. |
De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 2010, 376(9747): 1147-1154.
|
17. |
De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 2011, 364(21): 1995-2005.
|
18. |
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 2012, 367(13): 1187-1197.
|